Yan Ling-Ling, Wang Bei, Wang Long, Ma Wei-Kun, Jia Xiao-Bin, Feng Liang
School of Traditional Chinese Pharmacy, Chinese Pharmaceutical University Nanjing 211198, China.
Zhongguo Zhong Yao Za Zhi. 2023 Jan;48(1):30-38. doi: 10.19540/j.cnki.cjcmm.20220918.103.
Rare and endangered Chinese medicinal materials are the material basis for innovation and development of Chinese medicinal materials and their curative effects are remarkable. However, the resources are in shortage due to various man-made or natural factors such as rising demand, overexploitation and environmental degradation. Therefore, finding alternatives is a feasible and effective solution. This study systematically sorted out the list of rare and endangered Chinese medicinal materials, and combed relevant policies and regulations. According to existing research, the substitution model of rare and endangered Chinese medicinal materials was constructed from the theoretical level. In view of the slow search for substitutes, the failure to follow the basic theory of traditional Chinese medicine in the process of research and development, the difficulty in breaking through technologies and the incomplete guarantee of the clinical efficacy of substitutes, a multi-component replacement was proposed to replace the originals with more effective components from a wide range of sources. This study was expected to promote the study on the substitutes of rare and endangered Chinese medicinal materials to step into a new stage.
珍稀濒危中药材是中药材创新发展的物质基础，其疗效显著。然而，由于需求上升、过度开发和环境退化等各种人为或自然因素，资源短缺。因此，寻找替代品是一种可行且有效的解决方案。本研究系统梳理了珍稀濒危中药材名录，并梳理了相关政策法规。根据现有研究，从理论层面构建了珍稀濒危中药材替代模型。鉴于替代品寻找缓慢、研发过程未遵循中医基本理论、技术突破困难以及替代品临床疗效保障不完整等问题，提出多组分替代，即从广泛来源中用更有效成分替代原药材。本研究有望推动珍稀濒危中药材替代品研究步入新阶段。
